How much funding has Angiolab raised?

Angiolab has raised $7.1M in total funding, most recently a Seed round.

Who are Angiolab's investors?

Angiolab's investors include Korean Development Bank.

Where is Angiolab headquartered?

Angiolab is headquartered in Daejeon, South Korea.

What industry is Angiolab in?

Angiolab operates in Biotech, Healthcare.

Angiolab

Daejeon, South Korea · Founded 1999 · $7.1M raised

Biotech

Healthcare

Headquarters: Daejeon
Employees: 11–50
Founded: 1999
Business Model: B2B

Website: angiolab.co.kr
Total Funding: $7.1M
Last Round: $7.1M SeedJan 2006
Rounds: 1

About

AngioLab, Inc. is a South Korean biotechnology company specializing in the discovery and development of angiogenesis inhibitors and stimulators for therapeutic applications. The company develops pharmaceutical products targeting ophthalmic disorders (including macular degeneration), gastrointestinal conditions, psoriasis, obesity, and metabolic diseases, as well as cosmetic and functional food applications. With over 102 patents and a focus on the molecular mechanisms of angiogenesis — the process of new blood vessel formation — AngioLab conducts clinical trials and partners with pharmaceutical companies to advance its pipeline. The company is publicly listed on the Korean KOSDAQ exchange (stock symbol: 251280) and is headquartered in Daejeon, South Korea (Yuseong-gu district). Its research spans angiogenesis modulation across both inhibitory (cancer, AMD) and stimulatory (wound healing, ischemia) therapeutic axes.

Summary

Angiolab is a Biotech company based in Daejeon, South Korea, founded in 1999. It has raised $7.1M in total across 1 round, most recently a $7.1M Seed round in Jan 2006. Investors include Korean Development Bank.